Innocan Pharma Reports Second-Quarter Results with Revenue of US$5.25 Million

Innocan Pharma Corporation reported its second-quarter fiscal year 2026 results, with revenue of US$5.25 million (CAD 7.3M). The company's consumer wellness subsidiary, B.I. Sky Global Ltd., maintained a gross margin of 90.9% during the period.

The VALITIC brand, flagship skincare product of B.I. Sky, continued to lead in its category on Amazon and held the 'Best Seller' badge, reflecting strong consumer demand and growing brand strength.

In a statement, Iris Bincovich, CEO of Innocan Pharma Corporation, expressed pride in BI Sky's business performance and consumer trust built around their products.